MAPT and Alzheimer disease: The finding is consistent with a previous study showing that atDCS (50 μA, 0.0325 cm2, 20 min/day) for 15 days led no significant changes on APP and tau levels in AD mice (3xTg; 6–7 months) (Gondard et al., 2019).